“The KO-947 phase I program is on track for an on-time enrollment, with data expected in the second half of this year from the phase I study. Findings presented at AACR today could inform future clinical studies for KO-947, by targeting a subset of head and neck, and esophageal patients, based on a precision medicine model. We conclude that KO-947 continues to be a promising asset, based on preclinical data, but is not anticipated to have revenue impact to Kura Oncology by 2022; therefore, we are not making any adjustments to our estimates or outlook.”,” the firm’s analyst commented.
A number of other analysts have also recently weighed in on the stock. BidaskClub upgraded shares of Kura Oncology from a hold rating to a buy rating in a research note on Wednesday, January 24th. Citigroup set a $28.00 price objective on shares of Kura Oncology and gave the stock a buy rating in a research note on Friday, February 16th. Zacks Investment Research cut shares of Kura Oncology from a hold rating to a sell rating in a research note on Wednesday, January 10th. Finally, Wedbush initiated coverage on shares of Kura Oncology in a research note on Tuesday, December 26th. They issued a buy rating and a $19.00 price objective for the company. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $22.00.
Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Monday, March 12th. The company reported ($0.37) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.01). analysts anticipate that Kura Oncology will post -1.43 EPS for the current year.
Large investors have recently added to or reduced their stakes in the stock. MetLife Investment Advisors LLC acquired a new position in Kura Oncology during the 4th quarter valued at $155,000. American International Group Inc. raised its stake in Kura Oncology by 42.0% during the 4th quarter. American International Group Inc. now owns 13,574 shares of the company’s stock valued at $208,000 after purchasing an additional 4,012 shares during the last quarter. California State Teachers Retirement System acquired a new position in Kura Oncology during the 2nd quarter valued at $235,000. Virtus Fund Advisers LLC acquired a new position in Kura Oncology during the 4th quarter valued at $392,000. Finally, Goldman Sachs Group Inc. raised its stake in Kura Oncology by 48.8% during the 4th quarter. Goldman Sachs Group Inc. now owns 29,222 shares of the company’s stock valued at $447,000 after purchasing an additional 9,590 shares during the last quarter. Hedge funds and other institutional investors own 58.56% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://stocknewstimes.com/2018/04/21/kura-oncologys-kura-buy-rating-reaffirmed-at-cann.html.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.